Loading...
BRAF mutation is the most common genetic abnormality in patients with disseminated melanoma. The mutated BRAFV600E protein has become an important therapeutic target in these patients. VE1 is a new monoclonal antibody that can identify mutated BRAFV600E. These authors and the authors of another recent study assessed the sensitivity and specificity of VE1 for detecting BRAF mutations in primary and metastatic melanoma lesions.
These researchers examined 44 melanomas metastasized to skin, lymph node, soft tissue, lung, and other locations; of these, 22 were BRAFV600E-positive. They also examined 20 primary melanomas (10 superficial spreading type, 3 acral, 3 lentigo maligna, 3 nodular, and 1 spitzoid), 7 of which were BRAFV600E-positive. All m…